How to evaluate an AI scribe for community health services: a compliance and procurement checklist

Legal uncertainty is the single biggest barrier to AI adoption in European health systems, cited by 86% of countries in the World Health Organization (WHO)/Europe's 2024–2025 AI readiness assessment. For community health services — nurse-led, dispersed across schools, home visits, and local clinics — that uncertainty cuts even deeper. The published evidence on AI documentation tools is almost entirely drawn from hospitals and GP practices that look nothing like community settings.

This guide sets out what public health and community service administrators actually need to assess, and in what order.

First: be precise about what the tool does

An AI documentation assistant listens to a clinical conversation, converts speech to text, and drafts a structured note for the clinician to review. Interpreting findings, suggesting diagnoses, recommending treatment, and flagging clinical risk are functions of clinical decision support, and they carry different regulatory obligations under both the EU Medical Device Regulation (MDR) and the EU AI Act.

A practical test: if you removed the tool's output from a consultation and the clinician's judgement was unchanged, it's a documentation assistant. If the output would change what the clinician does next, it's decision support. Getting this distinction wrong at the start creates compliance problems that are expensive to unwind later.

Regulatory classification: MDR, AI Act, and GDPR

MDR classification

The central question is whether the tool has a medical intended purpose: diagnosis, prevention, monitoring, treatment, or alleviation of disease. A tool that only captures and structures conversation generally falls outside MDR scope. One that generates recommendations or risk scores falls inside it, and requires CE marking, a completed conformity assessment, and post-market surveillance.

The European Commission's Medical Device Coordination Group (MDCG) 2025-6 guidance confirms that where a tool qualifies as a medical device, MDR and AI Act obligations apply simultaneously. Ask any vendor for a written statement of intended purpose, confirmation of their MDR classification and its basis, CE marking documentation if applicable, and evidence of any Notified Body involvement. Osborne Clarke's analysis notes a genuine bottleneck in the number of Notified Bodies able to assess AI-based devices under both frameworks, so CE marking that has not yet been granted should not be treated as imminent.

GDPR, data residency, and the DPIA

An AI scribe processes special category health data under Article 9 of the General Data Protection Regulation (GDPR), which triggers the most stringent tier of obligations. The community service, as data controller, bears primary accountability. Before procurement, five things need to be resolved.

First, lawful basis. Community health programmes typically rely on Article 9(2)(h) alongside Article 6(1)(e) for public task; confirm with your Data Protection Officer (DPO) that this is documented. Second, an Article 28-compliant Data Processing Agreement (DPA) must be signed before any data flows, specifying purpose, duration, data types, and the obligations of both parties. Third, require contractual guarantees that patient data is stored and processed within the EU/EEA (or the UK for UK services), along with a full list of sub-processors and their locations. Fourth, confirm what the tool retains after a consultation, for how long, and under what deletion policy. Fifth, a Data Protection Impact Assessment under Article 35 is mandatory here, because AI processing of health data at scale is high-risk by definition. In the UK, the Information Commissioner's Office (ICO) guidance on AI and data protection sets out what that assessment needs to cover.

The European Health Data Space, in force since 2025, adds a further governance layer for EU services where patient data may cross borders.

Security baseline

ISO 27001, the international standard for information security management, is the baseline. No vendor without a current certificate in scope should be shortlisted for health data processing, regardless of what else they offer. Ask for the certificate, its scope, and the date of the last surveillance audit.

Beyond that, get written answers to the following: Who inside the vendor organisation can access patient data, and what audit trail records that access? Is data encrypted in transit and at rest? What is the vendor's contractual commitment to breach notification? GDPR requires regulatory notification within 72 hours, so the vendor needs to be able to support that timeline. How often does independent penetration testing take place? National health-data security frameworks in countries such as France, Germany, and the Netherlands may sit on top of ISO 27001, so check whether yours applies.

Does it actually work in community settings?

This is where hospital evidence stops transferring. Community health encounters happen in patients' homes and school clinics, with background noise and variable microphone quality affecting transcription accuracy in ways a fixed room does not. Connectivity is often unreliable, so establish whether the tool works offline and syncs later. Consultations are shorter and more conversational. Staff frequently cover clinical assessment, social care coordination, and public health monitoring within a single visit, so note templates need to reflect that breadth.

Ask vendors directly whether the tool has been deployed in community health, home visiting, or school health settings, and request performance data from those settings specifically. NHS England's guidance on ambient scribing is a useful UK reference for what a responsible evaluation should include. Tandem's own AI scribe documentation sets out how it handles integration and data handling for exactly this kind of assessment.

Language diversity is an equity issue, not a technical footnote

Community services often serve linguistically diverse populations. A tool that performs well in standard Dutch, German, or English may perform noticeably worse with accented speech, regional dialects, or code-switching, where speakers move between languages within a single conversation. For a service with a population health mandate, uneven accuracy has direct equity consequences: the patients most likely to be misrepresented in a clinical note are also the patients least likely to be well served by the health system in other ways.

Ask which language variants the tool has been validated in, what the documented accuracy gap is between standard and non-standard speech, and how it handles consultations conducted through an interpreter. Then test with staff and patients who reflect your actual population, including speakers of minority languages and regional dialects, rather than only the majority language group.

Running a structured pilot with thresholds set in advance

Don't leave accuracy assessment to the vendor. Define what a satisfactory note looks like for each encounter type in your service. Then run a time-limited pilot using real consultations, with independent review of AI-generated notes against clinician recall, and structured logging of errors, omissions, and hallucinations. A hallucination is content the AI generates that was never actually said.

Set your acceptance threshold before the pilot starts, so poor results can't be explained away afterwards. Build ongoing sample review into governance from day one. The clinician who conducted the encounter remains fully accountable for the note. The AI output is a draft for review, and training must say so unambiguously.

Governance and procurement: who to involve and when

Bring the DPO in at the start, not the end. The clinical governance lead should own quality standards and the pilot design; IT and security need to assess integration feasibility; legal should review contracts, the DPA, and liability under MDR and the AI Act. Procurement applies public procurement rules above threshold values, and clinical staff representatives need to shape requirements from the beginning, not be consulted after decisions are made. WHO/Europe found that 81% of EU Member States already involve stakeholders in shaping AI governance, which suggests multi-stakeholder engagement is becoming a baseline expectation at the national level.

Your business case should cover quantified reductions in paperwork burden, staff retention and burnout as a workforce argument, compliance as a risk obligation rather than an optional extra, and the cost of not acting.

The short checklist

Before go-live, you should be able to answer yes to all of these:

• Written intended-purpose statement and MDR classification received; AI Act classification assessed

• DPIA started and owned by the DPO; Article 28 DPA ready; EU/EEA (or UK) residency and full sub-processor list confirmed in writing

• Current ISO 27001 certificate in scope; access controls, audit logs, breach timelines, and penetration-test schedule confirmed

• Evidence of performance in community, home-visit, or school health settings, and offline capability confirmed

• Validated in your population's languages, tested with representative staff and patients

• Pilot designed with acceptance thresholds set in advance, and an ongoing review process in place

• DPO, clinical governance, IT, legal, procurement, and staff representatives all engaged

Of the frameworks cited here, The Lancet Primary Care framework is the most useful for community services specifically, because it insists on assessment against the actual delivery model rather than a generalised clinical encounter. With 92% of countries calling for clearer liability rules, the regulatory ground is still settling. That is an argument for starting with a clear, sequenced framework rather than making a technology-first purchase, not an argument for waiting.

Frequently asked questions

▶ Why do municipal community health programmes need a separate evaluation framework for AI documentation tools?

Hospital studies don't transfer because the delivery model is different. Community health runs across dozens of dispersed locations with no shared IT baseline, variable acoustics, and staff who often have no protected time to correct a draft note before the next visit begins.

▶ What does an AI documentation assistant actually do in a community health setting?

It listens, transcribes, and drafts a structured note for the clinician to review and approve. Anything that generates a recommendation, risk score, or clinical flag is decision support and sits in a different regulatory category with stricter obligations under both MDR and the AI Act.

▶ How does the EU Medical Device Regulation (MDR) apply to AI documentation tools?

Classification hinges on intended purpose. Pure transcription tools generally fall outside MDR scope. If a vendor's marketing or feature list implies clinical interpretation, ask for their written classification rationale and check whether a Notified Body was involved, since capacity constraints mean CE marking in progress should not be treated as equivalent to CE marking granted.

▶ What GDPR obligations apply when a municipality uses an AI documentation assistant to process patient data?

Health data is special category data under Article 9, the most stringent tier. The service, as controller, needs a documented lawful basis (typically Article 9(2)(h) with Article 6(1)(e)), an Article 28 Data Processing Agreement signed before any data flows, confirmed EU/EEA (or UK) residency, a full sub-processor list, and a mandatory Article 35 DPIA. The ICO's AI guidance sets out what that DPIA should cover.

▶ What security certifications and controls should administrators require from AI documentation vendors?

ISO 27001 is the baseline. Request the current certificate, its scope, and the last surveillance audit date. Also ask how quickly the vendor can notify you of a breach, because GDPR's 72-hour regulatory deadline runs from the moment the controller becomes aware, and a slow vendor notification compresses your response window significantly.

▶ Why might a hospital-validated AI documentation tool perform differently in community health settings?

Request performance data from community, home-visit, or school health deployments specifically. If a vendor can only supply hospital figures, treat that as a gap in the evidence base rather than a proxy for community performance, and factor it into your pilot design accordingly.

▶ Who is accountable for the accuracy of AI-generated clinical notes in a nurse-led community health service?

The clinician who conducted the encounter, fully. Training should address not just how to use the tool but how to recognise when a draft note misrepresents what was said, which requires supported practice with real consultations rather than a one-off onboarding session.

▶ How should administrators evaluate AI documentation tool accuracy before deploying across a community health programme?

Define what a satisfactory note looks like for each encounter type, run a time-limited pilot on real consultations with independent review, log errors, omissions, and hallucinations, and set your acceptance threshold before the pilot starts so results can't be rationalised afterwards. Then build ongoing sample review into governance permanently.

▶ How do we assess whether a tool can serve linguistically diverse community health populations?

Ask for documented accuracy figures broken down by language variant, and specifically for data on interpreter-mediated consultations, which are common in community settings and rarely covered in vendor validation studies. Test with staff and patients who reflect your actual population before any wider rollout.

▶ Which internal stakeholders need to be involved in procurement?

The DPO from the very start (owning the DPIA), a clinical governance lead (quality standards and the pilot), IT and security (integration), legal (contracts and liability under MDR and the AI Act), procurement (public procurement rules), and clinical staff representatives shaping requirements from the beginning. WHO/Europe found 81% of EU Member States already involve stakeholders in AI governance; the same principle applies at service level.